FDA Panel Reviews 7 Injectable Peptides Poised to Disrupt Telehealth and Longevity Care

For telehealth companies, med spas, and longevity clinics, the FDA’s review of seven popular injectable peptides is a watershed moment. These unproven therapies have become a core profit driver in the booming wellness space, but their regulatory status hangs in the balance. How the advisory committee weighs patient demand against the lack of clinical evidence will determine whether these compounds become a regulated healthcare product or remain a fringe risk.

The FDA’s Pharmacy Compounding Advisory Committee begins a pivotal two-day meeting on July 23, 2026, to evaluate whether compounding pharmacies should be permitted to produce seven widely-used injectable peptides—including TB-500, BPC-157, and MOTs-C. None of these compounds have undergone the large-scale clinical trials typically required for FDA drug approval, yet they have surged in popularity through direct-to-consumer telehealth platforms, med spas, and longevity clinics touting benefits for injury recovery, muscle growth, fat loss, and anti-aging.

“

Paul Knoepfler, a cell and molecular biologist at UC Davis, warns the therapies are “very risky” and “haven’t been scientifically proven,” reflecting broader concerns from the medical establishment.

The meeting marks a critical regulatory inflection point for an industry that has exploded in the absence of clear federal guidance. Peptide therapies have gained immense traction among consumers seeking performance enhancement and wellness, fueled by influential biohacking communities and aggressive online marketing. But the scientific foundation remains thin: no robust, randomized controlled trials establish their safety or efficacy. Paul Knoepfler, a cell and molecular biologist at UC Davis, warns the therapies are “very risky” and “haven’t been scientifically proven,” reflecting broader concerns from the medical establishment.

Under current Biden-era restrictions, many of these peptides are unavailable from traditional compounding pharmacies, pushing patients toward a vast gray market of unregulated overseas suppliers who sell vials of uncertain provenance. Industry advocates argue that these restrictions are counterproductive, driving consumers to riskier channels rather than allowing regulated pharmacies to produce the compounds under quality controls. They contend that permitting compounding would actually improve safety by bringing the supply chain into the light, even without formal FDA approval. This framing—that restrictive policy inadvertently fuels a dangerous underground—has become a central lobbying message ahead of the advisory committee’s review.